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Food allergy can result in considerable morbidity, impairment of quality of life and healthcare 
expenditure. There is therefore interest in novel strategies for its treatment, particularly food allergy 
allergen immunotherapy (FA-AIT) through the oral (OIT), sublingual (SLIT) or epicutaneous (EPIT) 
routes. This Guideline, prepared by the European Academy of Allergy and Clinical Immunology 
(EAACI) Task Force on Allergen Immunotherapy for IgE-mediated Food Allergy, aims to provide 
evidence-based recommendations for active treatment of IgE-mediated food allergy with FA-AIT. 
Immunotherapy relies on the delivery of gradually increasing doses of specific allergen to increase 
the threshold of reaction while on therapy (also known as desensitization) and ultimately to achieve 
post-discontinuation effectiveness (also known as tolerance or sustained unresponsiveness). Oral AIT 
has most frequently been assessed: here the allergen is either immediately swallowed (OIT) or held 
under the tongue for a period of time (SLIT). Overall, trials have found substantial benefit for patients 
undergoing either OIT or SLIT with respect to efficacy during treatment, particularly for cow’s milk, 
hen’s egg and peanut allergies. A benefit post-discontinuation is also suggested, but not confirmed. 
Adverse events during AIT have been frequently reported, but few subjects discontinue FA-AIT as a 
result of these. Taking into account the current evidence, AIT should only be performed in research 
centers or in clinical centers with an extensive experience in food allergy AIT. Patients and their 
families should be provided with information about the use of AIT for IgE-mediated food allergy to 
allow them to make an informed decision about the therapy.
Originally published as: Pajno GB, Fernandez-Rivas M, Arasi S, Roberts G, Akdis CA, Alvaro-Lozano M, Beyer K, 
Bindslev-Jensen C, Burks W, Ebisawa M, Eigenmann P, Knol E, Nadeau KC, Poulsen LK, van Ree R, Santos AF, du 
Toit G, Dhami S, Nurmatov U, Boloh Y, Makela M, O’Mahony L, Papadopoulos N, Sackesen C, Agache I, Angier E, 
Halken S, Jutel M, Lau S, Pfaar O, Ryan D, Sturm G, Varga EM, Gerth van Wijk R, Sheikh A, Muraro A, on behalf of 
EAACI Allergen Immunotherapy Guidelines Group. EAACI Guidelines on Allergen Immunotherapy: IgE-mediated 
Food Allergy © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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INTRODUCTION
Food allergy (FA) has emerged as a significant medical 
problem in recent decades. With FA now affecting up 
to 8% of children and 5% of adults in westernised 
countries, development of therapies for this 
potentially life-threatening condition has become a 
public health priority (1-3). The key terms and clinical 
presentation of FA are summarised in Boxes 1 and 2.
The current approach in managing FA focuses on 
avoidance of trigger foods and the availability of and 
training in the use of rescue medication in the event 
of an allergic reaction. Allergen immunotherapy (AIT) 
is potentially a curative therapy. AIT may increase 
the amount of food that the patient can tolerate, 
preventing allergic symptoms and reducing the risk 
of potentially life-threatening allergic reactions. The 
first case of immunotherapy for food allergy (FA-AIT) 
was described in 1908 to hen’s egg (HE) (4); the 
principles underlying the therapy have remained the 
same, i.e. therapy consists of the administration of 
gradually increasing doses of food allergens via the 
oral, sublingual or subcutaneous routes (2). A fixed 
dose of allergen can be administered through the 
epicutaneous route (2).
The ultimate goal of FA-AIT is to achieve post-
discontinuation effectiveness so that a patient can eat 
a normal serving of the trigger food without symptoms. 
This is also known as “tolerance” or “sustained 
unresponsiveness”. These terms all imply that the 
food allergen can be ingested without the appearance 
of allergic symptoms despite a period of absence of 
exposure. The time period required to establish true 
post-discontinuation effectiveness is not yet defined. 
Based on current evidence, a more attainable target 
is effectiveness during treatment (typically referred to 
as “desensitisation”) which refers to a reversible or 
partially reversible clinical response that is dependent 
on ongoing allergen exposure. If the administration 
of the allergen is discontinued, the previous level of 
clinical reactivity may return (5).
The primary outcome of FA-AIT is a change in the 
threshold of allergen required to trigger an allergic 
reaction determined by an oral food challenge (OFC) 
- where possible, this is preferably a double-blind, 
Allergen 
immunotherapy
Repeated allergen exposure at regular intervals to modulate immune response to reduce 
symptoms and the need for medication for clinical allergies and to prevent the development of 
new allergies. This is also known as allergen specific immunotherapy.
Effectiveness during 
treatment
The ability to safely consume foods containing the culprit allergen while on allergen 
immunotherapy. This clinical response is dependent on ongoing allergen exposure. If the 
administration of the allergen is discontinued, the previous level of clinical reactivity may return. 
This is also referred to as “desensitization”.
Food Any substance, whether processed, semi-processed, or raw, which is intended for human 
consumption, and includes drink, chewing gum, and any substance which has been used in the 
manufacture, preparation, or treatment of ‘food’ but does not include cosmetics or tobacco or 
substances used only as drugs [Codex Alimentarius]. Food is eaten, drunk or otherwise taken to 
the body to provide energy and nutritional support, maintain life, or stimulate growth.
Food allergy An adverse reaction to food mediated by an immunologic mechanism, involving specific-IgE 
(IgE-mediated), cell-mediated mechanisms (non-IgE-mediated) or both IgE- and cell-mediated 
mechanisms (mixed IgE- and non-IgE-mediated) [from EAACI Food Allergy and Anaphylaxis 
Guidelines (3)]. 
Post-discontinuation 
effectiveness
The ability to safely consume a normal serving of food containing the trigger allergen 
despite a period of absence of exposure. This is also known as “tolerance” or “sustained 
unresponsiveness”.
Sensitization Detectable IgE antibodies, either by means of skin prick test or determination of serum specific-
IgE antibodies.
Box 1 Key terms
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Systems Symptoms
Cutaneous pruritus, erythema/flushing, urticaria, angioedema, contact urticaria
Ocular itching, redness, tearing, periorbital edema
Oropharynx itching, dryness/discomfort, swelling of the oral cavity, lips, tongue and/or pharynx
Respiratory tract nasal congestion, nasal pruritus, rhinorrhea, sneezing hoarseness, laryngeal edema, 
dysphonia, shortness of breath, cough, wheezing, chest tightness/pain
Gastrointestinal  abdominal pain, nausea, emesis, diarrhea
Cardiovascular/Neurological tachycardia, hypotension, dizziness, loss of consciousness/fainting, seizures, incontinence
Multi-organ anaphylaxis 
Miscellaneous sense of impending doom, uterine cramping/contractions
Box 2 Clinical presentations of IgE-mediated food allergy
placebo-controlled, food challenge (DBPCFC). There 
is great variability in the threshold of exposure 
between different studies and for different foods 
(6, 7). Additional parameters have been studied in 
the monitoring of FA-AIT, including: skin prick tests 
(SPT) (8), specific-IgE (sIgE), IgG and IgG4 levels in 
serum (9). Some studies have also looked at basophil 
activation tests (BAT) (10), cytokines (e.g. IL-10, IL-5 
and IFN-γ) (11,12), and regulatory T-cells (13).
The most frequent route of administration of FA-
AIT is the oral route where the allergen is either 
immediately swallowed (oral immunotherapy, OIT) or 
held under the tongue for a period of time (sublingual 
immunotherapy, SLIT). There are currently ongoing 
studies using the subcutaneous route (subcutaneous 
immunotherapy, SCIT) for peanut and fish allergies (14-
16). Epicutaneous immunotherapy (EPIT) is also under 
investigation for peanut and cow’s milk (CM); it involves 
application of patches containing food allergen onto 
the skin (17). In general, there has been no consistent 
formulation of food in FA-AIT studies conducted to date 
(18). Dilutions of unprocessed products, crude extracts 
and flours have been used. Some studies have been 
carried out with powdered or lyophilized products. Only 
a few have used food extracts with a quantification of 
major allergens prepared by pharmaceutical companies 
or hospital pharmacies (11, 19).
This Guideline has been prepared by the European 
Academy of Allergy and Clinical Immunology 
(EAACI) Task Force on Allergen Immunotherapy for 
IgE-mediated Food Allergy. It is part of the EAACI 
Guidelines on Allergen Immunotherapy. This Guideline 
aims to provide evidence-based recommendations for 
the use of AIT in patients with diagnosed IgE-mediated 
FA. The primary audience are clinical allergists. This 
Guideline is also likely to be of relevance to other 
healthcare professionals (e.g. other doctors, nurses, 
dieticians, psychologists and paramedics) who are 
involved in the management of patients with food 
allergy and their families in any setting.
The development of this Guideline has been informed by 
a formal systematic review (SR) and meta-analysis on 
FA-AIT that included 31 trials studying 1259 patients. 
There were 25 randomised clinical trials (RCT) and 6 
non-randomised controlled clinical trials (CCT). OIT was 
covered by 25 studies, SLIT was used in 5, and EPIT in 1. 
The food allergies most frequently studied were CM (16 
studies), HE (11 studies), and peanut (7 studies) (18).
METHODOLOGY
This Guideline was produced using the Appraisal 
of Guidelines for Research & Evaluation (AGREE II) 
framework (20, 21), which is a structured approach 
to guideline production. This is designed to ensure 
appropriate representation of the full range of 
stakeholders, a careful search for and critical appraisal 
of the relevant literature, a systematic approach to the 
formulation and presentation of recommendations, 
and steps to ensure that the risk of bias is minimised 
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at each step of the process. The process started in 
April 2015 beginning with detailed face-to-face 
discussions agreeing on the process and the key 
clinical areas to address, followed by face-to-face 
meetings and web-conferences in which professional 
and lay representatives participated.
Clarifying the scope and purpose of the 
Guidelines
This Guideline aims to assist qualified clinicians in 
the optimal use of AIT in the management of patients 
with IgE-mediated FA, and highlight gaps for further 
research.
Ensuring appropriate stakeholder 
involvement
Participants in the EAACI Taskforce on FA-AIT 
represented a range of 16 countries, and different 
disciplinary and clinical backgrounds, including 
allergists, paediatricians, primary care physicians, 
immunologists and patient group representatives. 
Additionally, producers of AIT products were given 
the opportunity to review and comment on the draft 
Guideline.
Systematic review of the evidence
The initial full range of questions that were considered 
important were rationalized through several rounds 
of iteration to agree one key question: what is the 
effectiveness, changes in disease-specific quality 
of life (QoL), cost-effectiveness and safety of AIT in 
patients with IgE-mediated FA. This was then pursued 
through a formal SR of the evidence by independent 
methodologists as previously published (18) (Box 3). 
We continued to track evidence published after our SR 
cut-off date of 31st March 2016 and, where relevant, 
recent studies were considered by the Taskforce’s 
joint Chairs. This most recent evidence will formally 
be considered in the SR update that will precede the 
update of this Guideline.
Formulating recommendations
We assessed the strength, consistency and quality 
of evidence in relation to key findings from the SR 
and meta-analyses (18) (which were undertaken 
using random-effects models to take into account 
the heterogeneity of findings) to formulate evidence-
based recommendations for clinical care (Box 4) (22). 
This involved formulating clear recommendations 
with the strength of evidence underpinning each 
recommendation. Where the SR did not cover 
the clinical area, we took a hierarchical approach 
reviewing other evidence until we could formulate a 
recommendation, i.e. (i) other SRs on the subject to 
see if these provided any clarity on the topic; (ii) RCTs 
within these systematic reviews; (iii) other RCTs known 
to Taskforce members; and (iv) an expert consensus-
based approach. This evidence was also assessed, 
as described above. Experts identified the resource 
implications of implementing the recommendations, 
barriers, and facilitators to the implementation of 
each recommendation, advice on approaches to 
implementing the recommendations and suggested 
audit criteria that can help with assessing organisational 
compliance with each recommendation.
Aim To provide a systematic review of the evidence on the effectiveness, safety and cost-effectiveness of 
AIT for IgE-mediated food allergy.
Outcomes  
of the SR:
Primary
• Effectiveness during the treatment (i.e. the ability to safely consume foods containing the allergen in 
question while on AIT) or post-discontinuation effectiveness (the ability to consume foods containing 
the allergen in question after discontinuing AIT) at food challenge.
• Assessment of changes in disease specific quality of life (QoL) using a validated instrument.
Secondary
• Secondary outcome measures of interest were safety as assessed by local and systemic reactions in 
accordance with the WAO grading system of side-effects
• Health economic analysis from the perspective of the health system/payer as reported in studies.
Box 3 Summary of the aims and outcomes of the supporting systematic review (18)
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Peer review and public comment
A draft of this Guideline was externally peer-reviewed by 
invited external experts from a range of organisations, 
countries, and professional backgrounds. Additionally, 
the draft Guideline was made available on the EAACI 
Website for a 3-week period in May 2017 to allow 
a broader array of stakeholders to comment. All 
feedback was considered by the Taskforce and, where 
appropriate, final revisions were made in light of the 
feedback received. We will be pleased to continue to 
receive feedback on this Guideline, which should be 
addressed to the corresponding author.
Identification of evidence gaps
The process of developing this Guideline has identified 
a number of evidence gaps which we have prioritised.
Editorial independence and managing 
conflict of interests
The production of this Guideline was funded and 
supported by EAACI. The funder did not have any 
influence on the guideline production process, on 
its contents, or on the decision to publish. Taskforce 
members’ conflict of interests were taken into account 
by the Taskforce Chairs as recommendations were 
formulated. Final decisions about strength of evidence 
for recommendations were reviewed by methodologists 
who had no conflict of interests in this area.
Updating the guidelines
We plan to update this Guideline in 2021 unless there 
are important advances before then.
LEVEL OF EVIDENCE
Level I Systematic reviews, meta-analysis, randomized controlled trials
Level II Two groups, non-randomized studies (e.g., cohort, case-control)
Level III One group non-randomized (e.g., before and after, pre-test, and post-test)
Level IV Descriptive studies that include analysis of outcomes (single-subject design, case series)
Level V Case reports and expert opinion that include narrative literature, reviews, and consensus statements
GRADES OF RECOMMENDATION
Grade A Consistent level I studies
Grade B Consistent level II or III studies or extrapolations from level I studies
Grade C Level IV studies or extrapolations from level II or III studies
Grade D Level V evidence or troublingly inconsistent or inconclusive studies at any level
STRENGTH OF RECOMMENDATIONS
Strong Evidence from studies at low risk of bias
Moderate Evidence from studies at moderate risk of bias
Weak Evidence from studies at high risk of bias
Recommendations are phrased according to the strength of recommendation: strong, “is recommended”; moderate, “can be 
recommended”; weak, “may be recommended in specific circumstances”; negative, “cannot be recommended”.
Approach adapted from Oxford Centre for Evidence-based Medicine - Levels of Evidence and Grades of Recommendations 
(22). The adaptation involved providing an assessment of the risk of bias, based on the Cochrane risk of bias tool, of the 
underpinning evidence and highlighting other potentially relevant contextual information.
Box 4 Assigning levels of evidence and recommendations
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GENERAL CONSIDERATIONS 
BEFORE INITIATING AIT FOR 
IgE-MEDIATED FOOD ALLERGY
AIT is potentially indicated for patients with evidence of 
an IgE-mediated FA and in whom avoidance measures 
are ineffective, undesirable or cause severe limitations 
to a patient’s QoL. Prior to initiating AIT, confirming 
the diagnosis of IgE-mediated FA is mandatory. This 
requires a recent, clear clinical history of an acute 
reaction(s) after consumption of the triggering food. 
The presence of IgE to the triggering food should be 
established with SPT and/or sIgE. Where the diagnosis 
is unclear, an OFC is required. The baseline reaction 
threshold may be used to establish the efficacy of AIT 
in individual patients (Box 5).
Studies to date have enrolled patients with 
heterogeneous ages and clinical presentations (18). 
Studies have included infants and pre-school children 
who have tolerated FA-AIT safely (23, 24). However, 
the limited ability of young children to report early 
symptoms of allergic reactions should be considered. 
Furthermore, young children have a high likelihood of 
developing spontaneous tolerance, particularly to CM, 
HE, wheat and soy (25-31). Therefore, it might be 
more appropriate to wait for the natural acquisition 
of spontaneous tolerance before commencing AIT 
for these allergens (25-31). The right time to start 
may be around 4-5 years of age, but this should be 
decided on an individual basis.
FA-AIT is logistically demanding, time-consuming 
and most patients are affected by side effects. These 
are usually mild, but systemic reactions - including 
life-threatening anaphylaxis - may occur. AIT for FA 
should therefore only be undertaken in centres with 
professional training in FA care with the expertise, 
competencies and full resuscitation facilities to safely 
deliver this therapy and manage any complications, 
including anaphylaxis (Box 6). Only patients and 
families who understand the aim of the intervention 
and its risks, and are motivated and adherent should 
be considered for FA-AIT (Boxes S1 and S2 in the 
online). There are therefore many issues to be 
considered and discussed with the patient and family 
before commencing FA AIT (Box 7).
• Detailed medical history to establish current clinical 
reactivity to the food (recent reactions) 
• Allergy testing (skin prick tests-SPTs, with food 
allergen extracts or fresh foods) and/or specific IgE 
(sIgE) to food allergen extract(s) or component(s) 
(component resolved diagnosis, CRD)
• Oral food challenge (OFC)
Box 5 Diagnosis of IgE-mediated food allergy before 
initiating FA-AIT
Personnel Medical doctor and nurse trained and 
experienced in the diagnosis of food allergy 
including oral challenges, and trained 
and experienced in the recognition and 
treatment of allergic reactions including 
anaphylaxis.
Personnel should be able to provide at least 
12 hours of observation in case of adverse 
reactions related to AIT.
#Anesthesiology team or intensive care 
or equivalent team particularly trained 
in resuscitation on call, at hand within 5 
minutes.
Equipment Stethoscope
Sphygmomanometer
Pulse oximeter
Oxygen
Spirometer, peak flow meter
Laryngoscope(s), intubation tube(s), 
ventilation bag(s)
Heart defibrillator (knowledge and 
experience how to use it)
#Crash trolley
Medication Adrenaline (epinephrine), antihistamine 
(oral and parenteral), inhaled beta2-
agonist, corticosteroids (oral, parenteral).
IV lines and IV fluids
# According to the local facilities and organization of 
assistance to patients experiencing severe anaphylaxis.
Box 6 Personnel and equipment required to perform 
FA-AIT
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GENERAL 
CONTRAINDICATIONS
Given the long-treatment duration and common 
adverse reactions, any medical or social condition that 
might prevent patients attending frequent clinical visits, 
being aware of side effects or adhering to treatment 
represents an absolute contraindication. Uncontrolled 
asthma is also an absolute contraindication as it is 
associated with an increased risk of life-threatening 
systemic reactions (32). Well-controlled asthma is 
however not a contraindication for FA-AIT. Although 
a history of moderate to severe anaphylaxis to a food 
may be associated with more side effects, it is not a 
contraindication; these patients require appropriate 
evaluation before starting FA-AIT and close supervision 
particularly during the build-up phase. Uncontrolled, 
severe atopic dermatitis/eczema and chronic urticaria 
are relative contraindications given the risk of acute 
exacerbation while on AIT and because they can 
confound safety assessment of AIT. Therefore, both 
disorders should be controlled before AIT is initiated. 
The presence of eosinophilic esophagitis (EoE) or 
any other eosinophilic gastrointestinal disease is a 
contraindication for FA-AIT because of the risk these 
worsen whilst on FA-AIT (33, 34).
There is a lack of available data on the risks 
associated with FA-AIT in autoimmune disorders, 
severe medical conditions such as cardiovascular 
diseases, mastocytosis, or with the concomitant use 
of medications such as beta-blockers or angiotensin-
converting enzyme (ACE) inhibitors. However, the 
risk in other types of AIT has been assessed (35-
39): these conditions can be considered relative 
contraindications, and FA-AIT should only be used 
with caution when likely benefits outweigh risks (Box 
8). The final decision about starting AIT should be 
established on an individual basis in discussion with 
the patient and/or family.
EFFECTIVENESS OF DIFFERENT 
APPROACHES TO AIT FOR IgE-
MEDIATED FOOD ALLERGY
The effectiveness of FA-AIT has to be assessed in 
relation to the culprit food and route of administration.
Effectiveness of oral immunotherapy
A recently performed SR identified 23 trials: 18 RCTs 
and 5 CCTs (18). A meta-analysis of 22 of these trials 
involving 982 subjects revealed a substantial benefit 
for the patients (children and mixed population) 
undergoing OIT with CM, HE and peanut with respect 
to efficacy during treatment (RR 0.14, 95% CI 0.08, 
0.24) (18).
Confirmed, persistent, systemic IgE- mediated FA.
Consider the likelihood of spontaneous resolution of 
the specific FA (e.g. CM and HE allergies)
Patients and their families should be motivated, 
adherent and capable of administering emergency 
treatment (including intramuscular adrenaline) in case 
of adverse effects
Clinical centres undertaking FA-AIT should have the 
expertise and facilities to safely deliver this therapy. 
Box 7 General considerations before initiating FA-AIT 
Absolute • Poor adherence
• Uncontrolled or severe asthma
• Active malignant neoplasia(s)
• Active systemic, autoimmune disorders
• Active EoE or other gastrointestinal 
eosinophilic disorders
• Initiation during pregnancy
Relative FA-AIT should only be used with caution in 
an individual patient when benefits outweigh 
potential risks
• Severe systemic illness or severe medical 
conditions such as cardiovascular 
diseases
• Systemic autoimmune disorders in 
remission/organ specific (i.e. thyroiditis)
• Uncontrolled active atopic dermatitis/
eczema
• Chronic urticaria
• Beta-blockers
• ACE inhibitors
• Mastocytosis
Box 8 General contraindications to FA-AIT
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There were 7 studies included in the SR (18) that 
assessed post-discontinuation effectiveness, but only 
4 studies could be included in the meta-analysis (8, 
40-42). This analysis suggested but did not confirm 
the longer-term benefits of OIT (RR 0.29, 95% CI 
0.08, 1.13) (18). These 4 trials covered HE (8, 40-
42) (169 subjects) and CM (40) (25 subjects), and 
assessed effectiveness by an oral challenge performed 
after 1 to 3 months of discontinuation of OIT. No 
subgroup analysis on the type of food or period of 
discontinuation could be performed. In an egg OIT 
trial, published after our SR (43), post-discontinuation 
effectiveness of egg OIT was enhanced with duration 
of OIT; however, there was no control group in the 
follow-up period to compare with natural resolution of 
the egg allergy. In this trial children were treated for 
up to 4 years, whereas those included in the meta-
analysis were treated for a shorter period of time.
Regimens for OIT varied widely from rush protocols 
to slow up-dosing regimens with or without an initial 
dose escalation day (18). There was no apparent 
difference regarding effectiveness during treatment 
between CM, HE and peanut, and between the different 
protocols with all showing substantial effectiveness 
during treatment (18). The data published to date do 
not allow the ideal treatment regimen, including doses 
and intervals, to be determined. Additionally, the 
definition of effectiveness (i.e. increment of threshold) 
and its assessment varied among studies, and so the 
overall magnitude of the effect cannot be established.
In conclusion, FA-OIT is recommended for persistent 
CM, HE or peanut allergy for children from around 4 
to 5 years of age on the basis of its ability to increase 
the threshold for clinical reactions while on OIT (Grade 
A) (Table 1-3). At present, there are insufficient data 
to be able to recommend AIT for other foods (Table 4) 
and for adults outside clinical trials (Table 5).
Effectiveness of sublingual immunotherapy
There are few published studies which have assessed 
the effectiveness of SLIT. A recent meta-analysis 
identified four placebo-controlled RCTs and one CCT 
for the assessment of efficacy of SLIT while on therapy 
(18). The total number of patients treated was limited 
(n=189), and the food allergies covered included 
peanut (12, 52), hazelnut (11), and peach (53) in RCTs, 
and different foods in a CCT (50) (RR=0.26, 95% CI 
0.10, 0.64). Overall, SLIT revealed substantial benefits 
for the patients in regard to desensitization (18), R
ec
om
m
en
da
ti
on
s*
 
Ev
id
en
ce
 
le
ve
l
G
ra
de
 o
f r
ec
om
-
m
en
da
tio
n
St
re
ng
th
 o
f r
ec
om
m
en
da
tio
n 
O
th
er
 c
on
si
de
ra
tio
ns
K
ey
 r
ef
er
en
ce
s
O
IT
 is
 re
co
m
m
en
de
d 
as
 a
 tr
ea
tm
en
t o
pt
io
n 
to
 in
cr
ea
se
 th
re
sh
ol
d 
of
 re
ac
tio
n 
w
hi
le
 o
n 
tr
ea
tm
en
t i
n 
ch
ild
re
n 
w
ith
 p
er
si
st
en
t c
ow
´s
 m
ilk
 
al
le
rg
y,
 fr
om
 a
ro
un
d 
4
 -
 5
 y
ea
rs
 o
f a
ge
.
I
A
St
ro
ng
 re
co
m
m
en
da
tio
n 
ba
se
d 
on
 
co
nv
in
ci
ng
 e
vi
de
nc
e 
fr
om
 S
R
 a
nd
 
m
et
a-
an
al
ys
is
 (1
8
) i
nc
lu
di
ng
 R
CT
s 
at
 
lo
w
 (7
, 9
) o
r 
un
cl
ea
r 
ri
sk
 o
f b
ia
s 
(4
4
)
R
is
k 
of
 a
dv
er
se
 re
ac
tio
ns
 
ne
ed
s 
to
 b
e 
co
ns
id
er
ed
.
A
ge
 re
co
m
m
en
da
tio
n 
is
 
ba
se
d 
on
 e
xp
er
t o
pi
ni
on
. 
N
ur
m
at
ov
 2
0
1
7
 
(1
8
); 
Lo
ng
o 
2
0
0
8
 
(7
); 
Pa
jn
o 
2
0
1
0
 (9
); 
Sk
ri
pa
k 
2
0
0
8
 (4
4
)
A
 re
co
m
m
en
da
tio
n 
ca
nn
ot
 c
ur
re
nt
ly
 b
e 
m
ad
e 
fo
r 
O
IT
 a
s 
a 
tr
ea
tm
en
t o
pt
io
n 
in
 c
hi
ld
re
n 
w
ith
 
pe
rs
is
te
nt
 c
ow
’s
 m
ilk
 a
lle
rg
y 
w
ith
 th
e 
go
al
 o
f 
po
st
 d
is
co
nt
in
ua
ti
on
 e
ffe
ct
iv
en
es
s.
 
 I
B
W
ea
k 
as
 o
nl
y 
on
e 
sm
al
l R
CT
 a
t h
ig
h 
ri
sk
 o
f b
ia
s 
(4
0
) 
Fu
rt
he
r 
st
ud
ie
s 
ne
ed
ed
 S
ta
de
n 
2
0
0
7
 (4
0
) 
*O
IT
 fo
r 
fo
od
 a
lle
rg
y 
sh
ou
ld
 o
nl
y 
be
 u
nd
er
ta
ke
n 
in
 h
ig
hl
y 
sp
ec
ia
lis
ed
 c
lin
ic
al
 c
en
tr
es
 w
it
h 
ex
pe
rt
is
e 
an
d 
fa
ci
lit
ie
s 
to
 s
af
el
y 
de
liv
er
 t
hi
s 
th
er
ap
y.
Ta
bl
e 
1
 R
ec
om
m
en
da
ti
on
s 
on
 e
ffi
ca
cy
 o
f O
IT
 in
 c
hi
ld
re
n 
w
it
h 
pe
rs
is
te
nt
 c
ow
´s
 m
ilk
 a
lle
rg
y
59EAACI
EAACI Guideline: AIT for IgE-mediated Food Allergy
R
ec
om
m
en
da
ti
on
s*
 
Ev
id
en
ce
 
le
ve
l
G
ra
de
 o
f r
ec
om
-
m
en
da
tio
n
St
re
ng
th
 o
f r
ec
om
m
en
da
tio
n 
O
th
er
 c
on
si
de
ra
tio
ns
K
ey
 r
ef
er
en
ce
s
O
IT
 c
an
 b
e 
re
co
m
m
en
de
d 
as
 a
 tr
ea
tm
en
t 
op
tio
n 
to
 in
cr
ea
se
 th
e 
th
re
sh
ol
d 
of
 re
ac
tio
n 
w
hi
le
 o
n 
O
IT
 in
 c
hi
ld
re
n 
w
ith
 p
er
si
st
en
t 
he
n´
s 
eg
g 
al
le
rg
y,
 fr
om
 a
ro
un
d 
4
 -
 5
 y
ea
rs
 
of
 a
ge
.
I
B
M
od
er
at
e 
re
co
m
m
en
da
tio
n 
ba
se
d 
on
 
ev
id
en
ce
 fo
r 
eff
ec
t 
fr
om
 S
R
 a
nd
 m
et
a-
an
al
ys
is
 (1
8
) i
nc
lu
di
ng
 lo
w
 r
is
k 
of
 b
ia
s 
R
CT
s 
(8
, 4
2
). 
St
ud
ie
s 
ar
e 
al
l s
m
al
l 
w
ith
 s
om
e 
he
te
ro
ge
ne
ity
 in
 re
su
lts
. 
R
is
k 
of
 a
dv
er
se
 re
ac
tio
ns
 n
ee
ds
 to
 b
e 
co
ns
id
er
ed
.
A
ge
 re
co
m
m
en
da
tio
n 
is
 b
as
ed
 o
n 
ex
pe
rt
 o
pi
ni
on
. A
dd
iti
on
al
 la
rg
e 
st
ud
ie
s 
re
qu
ir
ed
. 
N
ur
m
at
ov
, 
2
0
1
7
 (1
8
); 
B
ur
ks
, 2
0
1
2
 
(8
); 
Ca
m
in
it
i 
2
0
1
5
 (4
2
) 
A
 re
co
m
m
en
da
tio
n 
ca
nn
ot
 c
ur
re
nt
ly
 b
e 
m
ad
e 
fo
r 
O
IT
 a
s 
a 
tr
ea
tm
en
t o
pt
io
n 
to
 
ac
hi
ev
e 
po
st
-d
is
co
nt
in
ua
ti
on
 e
ffe
ct
iv
en
es
s 
in
 c
hi
ld
re
n 
w
ith
 p
er
si
st
en
t h
en
´s
 e
gg
 a
lle
rg
y
I
B
 
St
ro
ng
 re
co
m
m
en
da
tio
n 
ba
se
d 
on
 
on
ly
 o
ne
 R
CT
 w
ith
 lo
w
 r
is
k 
of
 b
ia
s 
(4
3
) 
A
ft
er
 4
 y
ea
rs
 o
f O
IT
 5
0
%
 o
f s
ub
je
ct
s 
ac
hi
ev
ed
 s
us
ta
in
ed
 u
nr
es
po
ns
iv
en
es
s 
4
-6
 w
ee
ks
 a
ft
er
 s
to
pp
in
g 
O
IT
 (4
3
). 
Fu
rt
he
r 
st
ud
ie
s 
ne
ed
ed
. 
Jo
ne
s 
2
0
1
6
 
(4
3
)
* 
O
IT
 fo
r 
fo
od
 a
lle
rg
y 
sh
ou
ld
 o
nl
y 
be
 u
nd
er
ta
ke
n 
in
 h
ig
hl
y 
sp
ec
ia
lis
ed
 c
lin
ic
al
 c
en
tr
es
 w
it
h 
ex
pe
rt
is
e 
an
d 
fa
ci
lit
ie
s 
to
 s
af
el
y 
de
liv
er
 t
hi
s 
th
er
ap
y.
Ta
bl
e 
2
 R
ec
om
m
en
da
ti
on
s 
on
 e
ffi
ca
cy
 o
f O
IT
 in
 c
hi
ld
re
n 
w
it
h 
he
n’
s 
eg
g 
al
le
rg
y
R
ec
om
m
en
da
ti
on
s*
 
Ev
id
en
ce
 
le
ve
l
G
ra
de
 o
f r
ec
om
-
m
en
da
tio
n
St
re
ng
th
 o
f r
ec
om
m
en
da
tio
n 
O
th
er
 c
on
si
de
ra
tio
ns
K
ey
 r
ef
er
en
ce
s
O
IT
 is
 re
co
m
m
en
de
d 
as
 a
 tr
ea
tm
en
t o
pt
io
n 
to
 in
cr
ea
se
 th
e 
th
re
sh
ol
d 
of
 re
ac
tio
n 
w
hi
le
 o
n 
tr
ea
tm
en
t i
n 
ch
ild
re
n 
w
ith
 p
ea
nu
t a
lle
rg
y 
fr
om
 
ar
ou
nd
 4
-5
 y
ea
rs
 o
f a
ge
I
A
St
ro
ng
 re
co
m
m
en
da
tio
n 
ba
se
d 
on
 
co
ns
is
te
nt
 e
vi
de
nc
e 
fr
om
 S
R
 a
nd
 
m
et
a-
an
al
ys
is
 (1
8
) w
ith
 lo
w
 r
is
k 
of
 
bi
as
 R
CT
s 
(4
5
-4
7
) 
R
is
k 
of
 a
dv
er
se
 re
ac
tio
ns
 
to
 b
e 
co
ns
id
er
ed
. A
ge
 
re
co
m
m
en
da
tio
n 
is
 b
as
ed
 
on
 e
xp
er
t o
pi
ni
on
. 
N
ur
m
at
ov
 2
0
1
7
 (1
8
); 
N
ar
is
et
y 
2
0
1
5
 (4
5
); 
Ta
ng
, 2
0
1
5
 (4
6
); 
Va
rs
hn
ey
 2
0
1
1
 (4
7
)
A
 re
co
m
m
en
da
tio
n 
ca
nn
ot
 c
ur
re
nt
ly
 b
e 
m
ad
e 
fo
r 
O
IT
 a
s 
a 
tr
ea
tm
en
t o
pt
io
n 
to
 a
ch
ie
ve
 p
os
t 
di
sc
on
ti
nu
at
io
n 
eff
ec
ti
ve
ne
ss
 in
 c
hi
ld
re
n 
w
it
h 
pe
an
ut
 a
lle
rg
y 
I
B
St
ro
ng
 re
co
m
m
en
da
tio
n 
ba
se
d 
on
 
tw
o 
R
CT
s 
at
 lo
w
 r
is
k 
of
 b
ia
s 
(2
3
, 4
5
) 
In
co
ns
is
te
nt
 s
tu
dy
 
re
su
lts
.
Fu
rt
he
r 
st
ud
ie
s 
ne
ed
ed
. 
Vi
ck
er
y 
2
0
1
7
 (2
3
), 
N
ar
is
et
y 
2
0
1
4
 (4
5
)
* 
O
IT
 fo
r 
fo
od
 a
lle
rg
y 
sh
ou
ld
 o
nl
y 
be
 u
nd
er
ta
ke
n 
in
 h
ig
hl
y 
sp
ec
ia
lis
ed
 c
lin
ic
al
 c
en
tr
es
 w
it
h 
ex
pe
rt
is
e 
an
d 
fa
ci
lit
ie
s 
to
 s
af
el
y 
de
liv
er
 t
hi
s 
th
er
ap
y.
Ta
bl
e 
3
 R
ec
om
m
en
da
ti
on
s 
on
 e
ffi
ca
cy
 o
f O
IT
 in
 c
hi
ld
re
n 
w
it
h 
pe
rs
is
te
nt
 p
ea
nu
t 
al
le
rg
y
R
ec
om
m
en
da
ti
on
s*
 
Ev
id
en
ce
 
le
ve
l
G
ra
de
 o
f r
ec
om
-
m
en
da
tio
n
St
re
ng
th
 o
f r
ec
om
m
en
da
tio
n 
O
th
er
 c
on
si
de
ra
tio
ns
K
ey
 r
ef
er
en
ce
s
A
 re
co
m
m
en
da
tio
n 
ca
nn
ot
 c
ur
re
nt
ly
 b
e 
m
ad
e 
fo
r 
O
IT
 a
s 
a 
tr
ea
tm
en
t o
pt
io
n 
to
 in
cr
ea
se
 th
e 
th
re
sh
ol
d 
of
 re
ac
tio
n 
w
hi
le
 o
n 
tr
ea
tm
en
t i
n 
ch
ild
re
n 
al
le
rg
ic
 t
o 
ot
he
r 
fo
od
s 
(e
.g
. fi
sh
, w
he
at
, 
pe
ac
h)
 
II
B
W
ea
k 
re
co
m
m
en
da
tio
n 
ba
se
d 
on
 a
 
fe
w
 c
as
es
 re
po
rt
ed
 in
 o
ne
 R
CT
 a
t 
hi
gh
 r
is
k 
of
 b
ia
s 
(4
8
) a
nd
 tw
o 
CC
Ts
 a
t 
m
od
er
at
e 
ri
sk
 o
f b
ia
s 
(4
9
, 5
0
)
R
is
k 
of
 a
dv
er
se
 re
ac
tio
ns
 
to
 b
e 
co
ns
id
er
ed
 
Pa
tr
ia
rc
a,
 1
9
9
8
 (4
8
), 
Pa
tr
ia
rc
a,
 2
0
0
3
 (4
9
); 
Pa
tr
ia
rc
a,
 2
0
0
7
 (5
0
)
* 
O
IT
 fo
r 
fo
od
 a
lle
rg
y 
sh
ou
ld
 o
nl
y 
be
 u
nd
er
ta
ke
n 
in
 h
ig
hl
y 
sp
ec
ia
lis
ed
 c
lin
ic
al
 c
en
tr
es
 w
it
h 
ex
pe
rt
is
e 
an
d 
fa
ci
lit
ie
s 
to
 s
af
el
y 
de
liv
er
 t
hi
s 
th
er
ap
y.
Ta
bl
e 
4
 R
ec
om
m
en
da
ti
on
s 
on
 e
ffi
ca
cy
 o
f O
IT
 in
 c
hi
ld
re
n 
w
it
h 
pe
rs
is
te
nt
 a
lle
rg
ie
s 
to
 o
th
er
 fo
od
s 
EAACI Guideline: AIT for IgE-mediated Food Allergy
60 EAACI
but none of the studies included in the SR assessed 
post-discontinuation effectiveness. However, an open 
follow-up of a peanut SLIT trial in children and adults 
found only 11% of patients achieving tolerance after 
three years on SLIT and post-discontinuation of the 
AIT for 4-6 weeks (54).
Head-to-head trials of OIT versus SLIT
Two trials directly compared the efficacy of OIT and 
SLIT: the first focused on CM (55) and the second 
on peanut allergy (45). The first trial randomized 
30 children with CM allergy to SLIT alone or SLIT 
followed by OIT. This trial clearly showed that OIT 
after SLIT was more efficacious for desensitization 
and sustained unresponsiveness after six weeks off 
therapy to CM than SLIT alone (55). The second trial 
was a double-blind study involving 21 children with 
peanut allergy who were randomized to receive either 
active SLIT/placebo OIT or active OIT/placebo SLIT. 
As in the CM trial, OIT was far more effective than SLIT 
for the treatment of peanut allergy as the increased 
threshold was significantly greater in the active OIT 
group while on therapy (45). OIT would seem to 
be a better therapeutic option than SLIT, but it is 
associated with significantly more adverse reactions. 
Currently, we cannot recommend SLIT for FA due to 
the limited effectiveness.
Other routes of AIT under investigation
EPIT with unmodified allergens is currently under 
investigation for peanut and CM. Efficacy results of 
one placebo controlled RCT with peanut EPIT in 74 
subjects aged 4-25 years have shown an increase 
in the threshold of reaction while on therapy. This 
effect was higher in patients younger than 11 years 
of age (17). Moreover, SCIT with modified allergens 
is also under development (14-16). Two SCIT 
trials are currently ongoing: one using a chemically 
modified peanut extract (14) and another one using 
hypoallergenic recombinant parvalbumin for fish 
allergy (16). And finally, a phase 1 trial with modified 
peanut allergens administered by the rectal route has 
been conducted, but showed significant side effects, 
which led to early termination of the trial (56). At 
present, we cannot recommend EPIT or SCIT for FA-
AIT.F
oo
d
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SAFETY OF AIT
Alongside efficacy, safety is pivotal to any treatment. In 
AIT, safety is particularly important, as potential adverse 
events are mostly immediate onset, food-induced IgE-
mediated reactions, which can lead to anaphylaxis. 
Events related to safety have been highlighted in the 
studies addressed by the SR (18). The heterogeneity 
in the reporting formats reduced the number of studies 
that could be pooled in the meta-analysis. Despite 
this, it was shown that patients receiving the active 
preparation experienced significantly more reactions, 
both systemic and local, than those who received 
placebo (18). Recommendations on safety of AIT are 
shown in Table 6.
Oral immunotherapy
OIT to foods is associated with a large number of local 
reactions. These are mainly itching of the oropharynx, 
perioral rash, and mild abdominal pain and can be 
bothersome when they occur repeatedly. Local reactions 
may evolve into more severe systemic reactions, but 
only a minority of patients experiences these. Results 
for systemic reactions from five OIT studies and for 
local reactions from 7 studies were pooled in the meta-
analysis. Patients receiving active treatment had a higher 
risk of systemic reactions than those in the placebo 
group (RR of not experiencing a systemic reaction in 
controls: 1.16, 95% CI 1.03, 1.30) (18). OIT was also 
associated with a higher risk of local reactions (RR of not 
experiencing a local reaction in controls: 2.14, 95% CI 
1.47, 3.12) (18). No deaths have been reported in the 
meta-analysis (18). It is therefore recommended that 
patients are carefully monitored for local and systemic 
allergic reactions in FA-AIT, particularly during the up-
dosing phase of FA-OIT (Grade A).
Dosing with an empty stomach, irregular intake, 
exercise, infection, medication use, menses, and 
suboptimal control of asthma or of allergic rhinitis 
may increase the risk of reactions (59-63) especially 
during the maintenance phase(s) of OIT, when 
patients continue treatment at home. Although 
adverse reactions have been reported in the absence 
of these co-factors, patients should be informed and 
instructed on how to manage AIT in these situations 
(Boxes 9 and 10). It is recommended that a careful 
evaluation and explanation to the patient and his/her 
caregiver(s) of the risk of reactions during FA-AIT is 
undertaken before starting AIT (Grade C) (Table 6). R
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Additionally, a careful evaluation of levels of sIgE, SPT 
and concomitant asthma control is recommended 
before starting FA-AIT as high levels of sIgE and skin 
reactivity, and asthma have been found as risk factors 
for adverse events (Grade B) (Table 6).
Dose adaptations are made according to the severity of 
allergic reactions. In mild reactions, doses can remain 
the same according to the protocol. With repeated 
mild reactions, particularly when bothersome to the 
patient, dose increments may be stopped, or doses 
may even be reduced. With systemic reactions, doses 
are usually reduced, although it is not established if a 
reduction is necessary in all patients, particularly when 
reactions only develop in the presence of co-factors. 
In patients with systemic reactions, individualized 
schedules with a longer and slower up-dosing phase, 
and premedication (antihistamines, or omalizumab) 
may be considered (58). We suggest a case-by-
case evaluation of dose adaptation, and a thorough 
review of any underlying condition. The control of any 
concomitant allergic disease, and especially asthma, 
has to be optimal. Safety should remain the priority.
Sublingual immunotherapy
SLIT is associated with a lower risk of significant 
adverse events than OIT. In RCTs of SLIT (11, 12, 52-
54), systemic reactions have been uncommon (<0.5-
2.3% of doses) and generally mild, and appeared not 
to differ from those observed in the placebo treated 
patients. Meta-analysis of 2 SLIT studies (11, 53) 
did not show a significantly higher risk of systemic 
reactions in the active group (RR of not experiencing 
a systemic reaction in controls: 0.98, 95% CI 0.85, 
1.14) (18). The most common adverse events in 
SLIT trials were mild local reactions in the oropharynx 
(7-40% of patients), which can be observed during 
both the up-dosing and maintenance phases. A 
meta-analysis of local reactions with SLIT could not 
be undertaken due to different formats in reporting 
reactions between trials.
SCIT and EPIT
The experience with SCIT using whole peanut 
aqueous allergen extracts is limited, mostly due to 
the high number of severe adverse events (including 
severe anaphylaxis) (64, 65). SCIT studies are 
currently underway with hypoallergenic recombinant 
parvalbumin and chemically modified peanut extract. 
These modified allergens have reduced allergenicity, 
but their safety profiles have not been yet reported 
(14-16).
One phase II RCT of EPIT with peanut suggests a 
favorable safety profile (17). Although patch-site 
reactions were observed in more than 90% of active 
treated patients, most were mild. Non-patch-site 
reactions were observed in less than 20% of patients, 
were also mild and responded to oral antihistamines or 
topical corticosteroids. No reactions required adrenaline.
• Provision of individualized schedule, clearly written 
in simple non-medical language. It should include 
personal identification data (name, address, contact 
details of the parents, guardian, a next of kin, and 
family doctor).
• Copy of schedule should be kept by the patients or 
his/her caregiver(s), and their family doctor.
• Clear identification of food allergen to be 
administered during FA-AIT.
• Clear explanation that FA-AIT escalation dose(s) 
has to be administered in clinical specialized setting 
under strict medical supervision properly equipped 
for treatment of potentially severe allergic reactions.
• The risk of reaction caused by FA-AIT should be 
explained to the patient and his/her caregiver 
before starting FA-AIT.
• Provision of emergency kit with copy of emergency 
action plan and adrenaline auto-injector for 
treatment of anaphylaxis.
Box 9 Summary of the management
• Take dose daily
• Do not take dose on an empty stomach
• Do not go to the bed in the hour following a dose
• Do not do exercise in the 2-3 hours following a dose
• Reduce or withhold the dose during infections, 
asthma exacerbations, gastrointestinal diseases or 
menses.
Box 10 Practical recommendations for patients
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The clinical setting for food allergy AIT
FA-AIT should only be undertaken in a setting where 
the full spectrum of food allergy reactions - including 
life-threatening anaphylaxis - can be managed (Boxes 
6 and table 6). In particular, administration of initial 
doses and regular increments requires the presence of 
staff trained to manage anaphylaxis. Doses tolerated 
in the clinical setting are subsequently taken at home. 
Patients need clear instructions on how to detect an 
allergic reaction and its appropriate self-management. 
They also need to have on-hand appropriate 
medications including adrenaline auto-injectors. All 
dose increments have to be performed in a clinically 
specialized setting, and if no reactions are observed 
the same dose can be subsequently taken at home.
When to stop AIT after adverse reactions?
With repeated local adverse reactions and/or systemic 
adverse events, discontinuation of AIT should be 
discussed with the patient and/or family.
Long-term safety
Long-term safety is not addressed in trials; these 
predominantly focus on efficacy and short term safety. 
The development of EoE after OIT has been reported 
(33, 34, 62, 66). In a SR, new onset EoE was found 
in 2.7% (95% CI 1.7, 4.0). All the studies analyzed 
were retrospective with significant publication bias 
suggested by funnel plot analysis (33). It is therefore 
recommended to monitor patients for symptoms of 
new onset EoE which may appear in the course of FA-
OIT (Grade A).
ALLERGEN FACTORS THAT 
AFFECT THE EFFECTIVENESS 
AND SAFETY OF AIT
In the SR on FA-AIT, the majority of trials were on 
CM (n=16), HE (n=11) and peanut (n=7), with only 
1-3 studies for each of the other foods (18). AIT for 
CM, HE and peanut had similar efficacies in terms 
of desensitization with RR of 0.12 (95% CI 0.06, 
0.25), 0.22 (0.11, 0.45) and 0.11 (0.04, 0.31), 
respectively. Of note, in these pooled analyses, the 
majority of studies were OIT with just a few SLIT ones 
and the products differed (e.g. peanut flour for OIT 
versus a peanut extract for SLIT).
Seven trials on different foods (3 CM, 1 HE, 1 peanut, 
1 peach and 1 hazelnut; the latter two dealing with 
SLIT, and the remaining 5 with OIT) could be pooled for 
analysis regarding occurrence of systemic reactions. 
An increased risk of systemic reactions was observed 
with OIT, but a comparative subgroup analysis on the 
type of allergen could not be undertaken (18). For 
local reactions, milk seems more prone to cause side 
effects than egg although no statistically significant 
differences were found between them (milk 2.70, 
1.33, 5.47; egg 1.55, 1.09, 2.22) (18). In conclusion, 
there is no evidence that the efficacy and safety are 
affected by the type and nature of the food allergen 
used in AIT.
PATIENT FACTORS THAT 
AFFECT THE EFFICACY AND 
SAFETY OF AIT
Different patient factors have been suspected to 
affect the outcomes of FA-AIT, both in terms of 
efficacy and safety. Concerning patient age, the SR 
and meta-analysis found that FA-AIT is effective in 
reducing FA in children and a population of mixed 
ages with IgE-mediated FA to a range of foods. It is 
still unclear if AIT is effective for adults. There are no 
studies of OIT performed exclusively in adults and in 
those performed with mixed (i.e. children and adult) 
populations, efficacy could not be analyzed separately 
according to age (18). The only studies focused on 
adults used SLIT with hazelnut and peach, and showed 
an increase in threshold of reaction while on therapy 
(11, 53).
In the SR and meta-analysis on FA-AIT, there were 
insufficient data to analyze the role of other patient 
factors such as the number of culprit foods of clinical 
relevance, co-existence of asthma or other severe 
allergic disorders, on FA-AIT outcomes (18). Some 
studies have shown that patients with greater IgE-
sensitisation, lower threshold/higher severity and 
associated asthma are those with a higher frequency 
of adverse events (57, 58, 62). In a similar vein, some 
studies found that smaller SPT wheal size and lower 
sIgE levels have been associated with an increased 
likelihood of achieving desensitization and tolerance 
(67, 68). However, other studies did not find a 
significant correlation between pre-FA-AIT SPT/ sIgE 
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results and treatment success (45, 52), and some FA-
AIT studies have included children with severe FAs or 
anaphylaxis with elevated sIgE who were successfully 
treated with FA-AIT (7, 9). Two studies performed in 
children allergic to CM have shown that IgE recognition 
of peptides of CM proteins are biomarkers that predict 
safety and efficacy of CM-AIT (54, 61).
ADHERENCE TO AIT
Adherence to treatment is a crucial consideration 
both to ensure efficacy and safety of FA-AIT. Given 
that FA-AIT is time-consuming and burdened by 
potential side effects, patients and their families must 
be extremely adherent, reliable and committed to a 
treatment regimen that may cover a long period of 
time. Given these premises, poor adherence to the 
treatment is an absolute contraindication (Box 8). 
A clear and detailed explanation about the FA-AIT 
procedure (i.e. up-dosing schedules, setting), the 
related outcomes and risk of side effects, together 
with getting information on patients’ and/or families’ 
opinions and expectations are pre-requisites to the 
inclusion in the treatment protocol. Patients and 
their families need to be supported during the entire 
treatment. Informed consent should be signed by 
patients (where appropriate) and their parents.
SUMMARY, GAPS IN THE 
EVIDENCE AND FUTURE 
PERSPECTIVES
FA-AIT represents the active treatment of IgE-
mediated FA instead of avoidance and rescue drug 
management. The usual management of FA demands 
changes in eating habits with serious repercussions on 
QoL, potential risk of nutritional deficiencies, especially 
in young children, and severe adverse reaction in case 
of accidental exposure to the culprit food.
The recent SR and meta-analysis on FA-AIT (18) clearly 
demonstrated that FA-AIT is effective in reducing 
the likelihood of reacting to foods while receiving 
the therapy. In pediatric patients with FA to CM and 
peanut, data suggest that OIT is more effective than 
SLIT (45, 55). There is an increased risk of local (the 
most frequent) reactions with both OIT and SLIT but 
only OIT showed a significantly higher risk of systemic 
reactions. Due to the length of the protocol and safety 
issues, patients and their families must be extremely 
adherent, reliable and committed to the treatment. 
FA-AIT may improve QoL scores, particularly with 
regard to social limitations, accidental exposure and 
anxiety, although further studies are needed (5).
Many children with CM allergy or HE allergy develop 
tolerance spontaneously. For this reason, for many 
patients and families, allergen avoidance whilst 
awaiting spontaneous resolution may represent a 
better option than FA-AIT. Therefore, FA-AIT cannot 
be recommended as routine practice, but must be 
limited only to carefully selected patients managed 
in specialized clinical settings, by trained personnel 
(Boxes 9 & 10).
There are still many gaps that need to be addressed 
(Table 7). The duration of FA-AIT may be burdensome 
for patients and their families. After completion of 
therapy, patients frequently need to continue to 
consume the allergen to maintain tolerance. It may be 
easier to achieve post-discontinuation effectiveness 
(e.g. tolerance or sustained unresponsiveness) for 
allergens that are typically outgrown in childhood 
(e.g. CM and HE) compared to other allergens (such 
as peanut), where probably lifelong ingestion may be 
required after therapy. In addition, efficacy during the 
treatment with CM can be maintained with a twice-
weekly regimen. We await maintenance follow-up 
studies to assess whether more flexible regimens are 
possible with other foods (69).
The quality of allergen preparations is critical for 
both diagnosis and treatment. Standardized allergen 
preparations of known potency and shelf-life should be 
used. Currently, the allergens containing food protein 
and those prepared by pharmaceutical companies or 
hospital pharmacies are not available as standardized 
products. The allergens in such products should 
be well characterized as it is known that different 
formulations of a product may have significant 
variations in allergen load. Both the bacteriological 
load and biological activity of these products are still 
undetermined. Therefore, the use of fresh material 
or native foods for FA-AIT is advisable to achieve 
the goal of desensitization. Different disciplinary and 
clinical backgrounds including medical care, patient 
groups, allergen manufacturers and regulators should 
be involved in the process of producing new data on 
standardized allergen preparations for the active 
treatment of FA.
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Novel therapeutic approaches are being developed 
to improve FA-AIT, most of them in pre-clinical or 
early clinical trials. In particular, co-administration 
of humanized monoclonal anti-IgE (omalizumab) 
seems to markedly reduce adverse reactions due 
to OIT compared to placebo (70-72). Furthermore, 
as bacteria are potent stimulants of Th1 immune 
responses, modified bacterial products are under 
investigation as adjuvants for FA-AIT (46).
Clinical studies carried out with FA-AIT have some 
limitations, a key one is the heterogeneity in protocols 
between centers. It is yet unclear which duration 
and frequency of ingestion of the allergic food(s) is 
required to maintain desensitization. Furthermore, 
Gaps in the evidence of FA AIT Plan to address Priority
Standardized products Collaboration between clinical investigators, regulators. High
Establish validated protocols with optimal dosing 
and duration of therapy
Analysis of existing data
New observation and controlled trials
Consensus discussion
High
Treatment of patient suffering from persistent 
allergies to multiple foods
Analysis of existing data
New observation and controlled trials
Consensus discussion
High
Definition of clinically relevant outcomes of 
effectiveness
Analysis of existing data
New observation and controlled trials
Consensus discussion with patients, clinicians and regulators
Development and validation of relevant outcomes
High
Continued effectiveness after FA-AIT 
discontinuation 
Analysis of existing data
New observation and controlled trials
Development and validation of relevant outcomes
High
Safety of FA-AIT during up-dosing and 
maintenance phases
Analysis of existing data
Establish a standardized European registry of systemic 
adverse events
New observation and controlled trials
High
Impact on QoL (patient-related outcomes) Development and validation of relevant outcomes
New observation and controlled trials
High
Cost-effectiveness New observation and controlled trials High
Advanced insight in the mechanisms of action Collaborative research using biological samples (biobanks) of 
patients already treated.
New observation and controlled trials 
High
Identification markers of response Analysis of existing data and biological samples
New controlled trials
High
Identification the most suitable candidates 
(personalized care)
Analysis of existing data and biological samples
New controlled trials
High
“Precision medicine” algorithms for patient 
tailored (individual) treatments
Analysis of existing data
Consensus discussion
Medium
Standardized nomenclature according to 
clinical needs, newly developing treatments and 
mechanisms
Consensus discussion Medium
Role of the different routes of administration Randomised controlled trials Medium
Effect of concomitant administration of anti-IgE 
on safety, efficacy and length of therapy
Analysis of existing data
New controlled trials
Medium
Effect of concomitant administration of probiotics 
on safety, efficacy, and length of therapy 
Controlled trials Low
Table 7 Gaps in the evidence for FA-AIT
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we are lacking criteria with which to evaluate and 
diagnose permanent tolerance. In AIT trials and 
in clinical practice, safety is of the paramount 
importance: strategies for improving safety during 
either up-dosing protocol or maintenance regimen 
need to be standardized. Managing these pivotal 
issues is mandatory for use of OIT/SLIT outside 
research settings or specialized clinical centers for 
FA-AIT.
FA-AIT should be utilized for patients with persistent 
food allergy (Box 11). In many patients, the 
downside of the adverse events associated with 
treatment is outweighed by both the achievement 
of desensitization and the reduced risk of a serious 
allergic reaction by accidental exposure at home or 
in the community. Considering the current evidence, 
there are still considerable knowledge gaps about how 
best to perform FA-AIT and more well-designed AIT 
trials are required.
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• FA- AIT should be considered for children from around 4 - 5 years of age with symptoms suggestive of persistent 
IgE-mediated food allergy to cow’s milk (Grade A), hen’s egg (Grade B) or peanut (Grade A) plus evidence of IgE 
sensitization to the triggering allergen.
• The majority of children allergic to milk and egg develops tolerance spontaneously. For these patients, waiting to see if 
they outgrow their allergies, before initiating FA- AIT, represents a sensible option.
• Among FA-AIT routes, OIT affords better efficacy than SLIT; however OIT is associated with higher frequency of 
adverse events compared with SLIT; adverse events may occur either during build - up phase and with maintenance 
phase but most of them are not severe.
• Currently, for OIT FA-AIT the use of fresh material or native foods is advisable.
• Key contraindications are: poor adherence; uncontrolled or severe asthma, active systemic autoimmune disorders; 
active malignant neoplasia; eosinophilic esophagitis. Careful review of benefits and risks are required with active 
severe atopic dermatitis, chronic urticaria, cardiovascular diseases, beta-blocker or ACE inhibitor therapy.
• FA-AIT should be administered by competent personnel with immediate access to resuscitation equipment and a 
doctor trained in managing anaphylaxis. 
• The initial FA-AIT dosage and each increased dosage during the build-up phase should be performed in clinical setting.
Box 11 Key messages
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